BioSpace News Archive

Drug Development

Rapid Whole Genome Sequencing in Infants Could Even Playing Field for Treatment

What if infants with genetic illnesses could be diagnosed in a matter of days? New research surrounding rapid whole genome sequencing suggests that soon, they could be.

April 10, 2022
·
9 min read
·
Rosemary Scott
Drug Development

Triumvira Immunologics to Present Two Posters Covering Ongoing Phase 1/2 Solid Tumor Trial and New Preclinical Gastric Cancer Data at AACR Annual Meeting 2022

Triumvira Immunologics announced it will present two posters at the American Association for Cancer Research Annual Meeting, taking place April 8-13, 2022 in New Orleans.

April 10, 2022
·
4 min read
Biotech Bay

Lumakras® (Sotorasib) Codebreak 100 Study Shows Two-year Overall Survival Of 32.5% In Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

Amgen announced the presentation of long-term efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C-mutated advanced non-small cell lung cancer who received LUMAKRAS® *.

April 10, 2022
·
17 min read
Pharm Country

Gennao Bio Presents Promising New Results from its Gene Monoclonal Antibody (GMAB) Platform at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, announced promising preclinical results of its proprietary, non-viral gene monoclonal antibody platform in multiple solid tumor models at the American Association for Cancer Research 2022 Annual Meeting.

April 10, 2022
·
3 min read
Drug Development

Gannex Announces First Patient Dosed in Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis

Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. announces the first patient dosed in the Phase II clinical trial of ASC42 to treat patients with primary biliary cholangitis.

April 10, 2022
·
5 min read
Genetown

Myeloid Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Ability of its ATAK™ Receptors and in vivo Delivery of mRNA to Attack Cancer by Immune Reprogramming

Myeloid Therapeutics, Inc. presented new late-breaking data at the American Association for Cancer Research Annual Meeting, being held in New Orleans, LA, April 8-13, 2022.

April 10, 2022
·
3 min read
Business

Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab

Telix Pharmaceuticals Limited announces that it has entered into a licence agreement with Eli Lilly and Company under which Telix is granted exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly’s olaratumab antibody for the diagnosis and treatment of human cancers.

April 10, 2022
·
8 min read
Drug Development

Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022

Innovent Biologics, Inc. announced that the results of the Phase I study for IBI322 in patients with advanced solid tumors were presented at the American Association for Cancer Research Annual Meeting 2022.

April 10, 2022
·
7 min read
Drug Development

Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, provided a data update from the ongoing study of the Company’s lead innate cell engager AFM13 precomplexed with cord blood-derived natural killer cells.

April 10, 2022
·
9 min read
Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Antengene Corporation Limited announced the publication of five posters that will be presented during the upcoming 2022 American Association for Cancer Research Annual Meeting, taking place from April 8th to April 13th in New Orleans in person or via virtual attendance.

April 10, 2022
·
10 min read